Cargando…
Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy
BACKGROUND: To date, no systemic therapy, including immunotherapy, exists to improve clinical outcomes in metastatic uveal melanoma (UM) patients. To understand the role of immune infiltrates in the genesis, metastasis, and response to treatment for UM, we systematically characterized immune profile...
Autores principales: | Qin, Yong, Bollin, Kathryn, de Macedo, Mariana Petaccia, Carapeto, Fernando, Kim, Kevin B, Roszik, Jason, Wani, Khalida M, Reuben, Alexandre, Reddy, Sujan T, Williams, Michelle D, Tetzlaff, Michael T, Wang, Wei-Lien, Gombos, Dan S, Esmaeli, Bita, Lazar, Alexander J, Hwu, Patrick, Patel, Sapna P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7674090/ https://www.ncbi.nlm.nih.gov/pubmed/33203661 http://dx.doi.org/10.1136/jitc-2020-000960 |
Ejemplares similares
-
Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study
por: Qin, Yong, et al.
Publicado: (2017) -
T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy
por: Stephen, Bettzy, et al.
Publicado: (2023) -
Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma
por: Reschke, Robin, et al.
Publicado: (2021) -
TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment
por: Kawashima, Shusuke, et al.
Publicado: (2021) -
uPAR(+) extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patients
por: Porcelli, Letizia, et al.
Publicado: (2021)